A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
第1/2相
完了
NCT05827926
| 対象疾患 | SARS-CoV-2, Influenza |
|---|
| 相 | 第1/2相 |
|---|
| スポンサー | ModernaTX, Inc. |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 1,758 名 |
|---|
| 介入（薬剤） | Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1 |
|---|
| 開始日 | 2023年4月14日 |
|---|
| 完了日 | 2024年12月3日 |
|---|
| 結果公開日 | 2025年12月23日 |
|---|
概要
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.
Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Up to 7 days after study injection · Participants
| Part 1 Cohort A12: Influenza Vaccine 1 | 32 Participants |
|---|
| Part 1 Cohort A13: Influenza Vaccine 2 | 36 Participants |
|---|
| Part 1 Cohort A11: Investigational Influenza Vaccine 2 | 37 Participants |
|---|
| Part 1 Cohort A8: Investigational Influenza Vaccine 1 | 43 Participants |
|---|
| Part 1 Cohort A10: COVID-19 Vaccine 1 | 42 Participants |
|---|
| Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | 31 Participants |
|---|
Parts 1 and 2: Number of Participants With Unsolicited Adverse Events (AEs) and Severe AEs
Up to 28 days after study injection · Participants
| Part 1 Cohort A12: Influenza Vaccine 1 | 5 Participants |
|---|
| Part 1 Cohort A13: Influenza Vaccine 2 | 9 Participants |
|---|
| Part 1 Cohort A11: Investigational Influenza Vaccine 2 | 7 Participants |
|---|
| Part 1 Cohort A8: Investigational Influenza Vaccine 1 | 5 Participants |
|---|
| Part 1 Cohort A10: COVID-19 Vaccine 1 | 7 Participants |
|---|
| Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | 9 Participants |
|---|
Parts 1 and 2: Number of Participants With Unsolicited Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
Day 1 through Day 181 · Participants
| Part 1 Cohort A12: Influenza Vaccine 1 | 2 Participants |
|---|
| Part 1 Cohort A13: Influenza Vaccine 2 | 2 Participants |
|---|
| Part 1 Cohort A11: Investigational Influenza Vaccine 2 | 1 Participants |
|---|
| Part 1 Cohort A8: Investigational Influenza Vaccine 1 | 1 Participants |
|---|
| Part 1 Cohort A10: COVID-19 Vaccine 1 | 2 Participants |
|---|
| Part 1 Cohort A9: Investigational COVID-19 Vaccine 1 | 1 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。